Lenalidomid Medical Valley (Lenalidomide)

Lenalidomide is employed in hematologic malignancies that rely on abnormal plasma or lymphoid cells.

• Multiple myeloma: helps control disease progression and improve survival in patients with relapsed or refractory disease.
• Myelodysplastic syndromes: reduces transfusion dependence and delays transformation to acute leukemia.
• Mantle cell lymphoma: contributes to disease control in patients who have received prior therapies.

• Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. This leads to modulation of cytokine production, inhibition of angiogenesis, and induction of apoptosis in malignant cells, while enhancing immune‑mediated tumor cell clearance.

Lenalidomid Medical Valley may cause a range of adverse reactions.

Common Side Effects

• Fatigue: persistent tiredness reported by many patients.
• Neutropenia: reduced neutrophil count increasing infection risk.
• Thrombocytopenia: lowered platelet levels that may cause easy bruising.
• Diarrhea: loose stools occurring during treatment.
• Rash: skin irritation or erythema.
• Constipation: difficulty passing stool.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Secondary primary malignancies: emergence of new cancers unrelated to the original disease.
• Severe neutropenia: profound drop in neutrophils requiring medical intervention.
• Hepatic failure: significant liver dysfunction.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.
• Interstitial lung disease: inflammation of lung tissue leading to breathing difficulties.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters.

• Pregnancy: contraindicated (Category X); avoid use in pregnant women.
• Thrombosis risk: assess history of clotting disorders and consider prophylaxis.
• Renal impairment: dose adjustment may be required in patients with reduced kidney function.
• Hematologic monitoring: perform regular complete blood counts to detect cytopenias.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Lenalidomid Medical Valley can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: may markedly lower lenalidomide exposure and reduce efficacy.
• Anticoagulants: concurrent use can increase bleeding risk.
• Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• Macrolide antibiotics (e.g., erythromycin): may raise lenalidomide plasma levels.
• Azole antifungals (e.g., ketoconazole): potential increase in drug concentration.
• Other immunosuppressants: may amplify overall immunosuppressive effect.